Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H39N7O9 |
| Molecular Weight | 617.6508 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]2CCCN2C(=O)[C@@H](CC3=CC=C(O)C=C3)NC(C)=O)C(=O)NCC(N)=O
InChI
InChIKey=GFJRASPBQLDRRY-TWTQBQJDSA-N
InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1
| Molecular Formula | C28H39N7O9 |
| Molecular Weight | 617.6508 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Rotigaptide (previously known as ZP123) originally was developed by Zealand Pharma as a stable antiarrhythmic peptide analog, which maintains gap junction intercellular communication. Then this drug was licensed to Wyeth Pharmaceuticals where it studied in phase II clinical trials in patients with coronary artery disease and with atrial fibrillation. However, these researches have been discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:00:17 GMT 2023
by
admin
on
Sat Dec 16 16:00:17 GMT 2023
|
| Record UNII |
GFA1W6KO7N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152260
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
DB13067
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
ROTIGAPTIDE
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
RR-54
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
9938933
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
C477643
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL450656
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
355151-12-1
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
DTXSID80189024
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
GFA1W6KO7N
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY | |||
|
8717
Created by
admin on Sat Dec 16 16:00:17 GMT 2023 , Edited by admin on Sat Dec 16 16:00:17 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> ACTIVATOR |
Rotigaptide has been shown to activate various protein kinase C (PKC) isoforms to cause the phosphorylation of Cx43, Rotigaptide (RG, ZP123) prevents of dephosphorylation and thereby uncoupling of 24 Connexin-43 (Cx43), possibly via action on unidentified protein phosphatases.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
